KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Return on Capital Employed: 2021-2025

Historic Return on Capital Employed for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Sep 2025 value amounting to -0.61%.

  • Recursion Pharmaceuticals' Return on Capital Employed rose 1.00% to -0.61% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.61%, marking a year-over-year increase of 1.00%. This contributed to the annual value of -0.55% for FY2024, which is 4.00% up from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Return on Capital Employed stood at -0.61%, which was down 6.14% from -0.57% recorded in Q2 2025.
  • Recursion Pharmaceuticals' 5-year Return on Capital Employed high stood at -0.23% for Q3 2021, and its period low was -0.71% during Q1 2024.
  • Its 3-year average for Return on Capital Employed is -0.58%, with a median of -0.57% in 2025.
  • Per our database at Business Quant, Recursion Pharmaceuticals' Return on Capital Employed fell by 25bps in 2024 and then climbed by 24bps in 2025.
  • Quarterly analysis of 5 years shows Recursion Pharmaceuticals' Return on Capital Employed stood at -0.31% in 2021, then dropped by 13bps to -0.44% in 2022, then fell by 20bps to -0.64% in 2023, then increased by 11bps to -0.53% in 2024, then rose by 1bps to -0.61% in 2025.
  • Its last three reported values are -0.61% in Q3 2025, -0.57% for Q2 2025, and -0.46% during Q1 2025.